Myriad Genetics has expanded collaboration with AbbVie to accelerate development of the latter’s investigational PARP inhibitor, veliparib.
The companion diagnostics (CDx) research collaboration builds on an existing partnership established in November 2014, in which Myriad and AbbVie are working to support Phase 3 clinical studies of veliparib for patients with breast cancer or ovarian cancer.
Go deeper with GlobalData
As part of the expanded partnership, AbbVie will use Myriad’s CDx portfolio, myChoice HRD, and new tumour tests to help identify patients with non-small cell lung cancer who are likely to respond to treatment with the combination of veliparib and chemotherapy.
Myriad Genetics chief scientific officer Jerry Lanchbury said: "As a company committed to innovation in the field of oncology, this collaboration with AbbVie enables us to use our proprietary companion diagnostics to advance care for patients with lung cancer.
"If we are successful, our companion diagnostics will identify more patients who may benefit from treatment with the combination of veliparib and chemotherapy."
In a separate development, Myriad has also entered into a research collaboration with Tesaro and Merck to evaluate treatment response in patients with triple negative breast cancer or ovarian cancer.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe patients will be administered an investigational combination drug therapy using TESARO’s PARP inhibitor (niraparib) along with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab).
The treatment response will be evaluated by using Myriad’s myChoice HRD test and new tumour tests.
Since March 2014, Myriad has been working with TESARO to use the myChoice HRD test for identifying ovarian cancer patients who may respond to niraparib, which is in Phase III clinical development.
